535 related articles for article (PubMed ID: 28686500)
1. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Allen TC; Attanoos RL; Beasley MB; Butnor KJ; Chirieac LR; Churg AM; Dacic S; Galateau-Sallé F; Gibbs A; Gown AM; Krausz T; Litzky LA; Marchevsky A; Nicholson AG; Roggli VL; Sharma AK; Travis WD; Walts AE; Wick MR
Arch Pathol Lab Med; 2018 Jan; 142(1):89-108. PubMed ID: 28686500
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
Husain AN; Colby T; Ordonez N; Krausz T; Attanoos R; Beasley MB; Borczuk AC; Butnor K; Cagle PT; Chirieac LR; Churg A; Dacic S; Fraire A; Galateau-Salle F; Gibbs A; Gown A; Hammar S; Litzky L; Marchevsky AM; Nicholson AG; Roggli V; Travis WD; Wick M;
Arch Pathol Lab Med; 2013 May; 137(5):647-67. PubMed ID: 22929121
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Krausz T; Borczuk A; Cagle PT; Chirieac LR; Churg A; Galateau-Salle F; Gibbs AR; Gown AM; Hammar SP; Litzky LA; Roggli VL; Travis WD; Wick MR
Arch Pathol Lab Med; 2009 Aug; 133(8):1317-31. PubMed ID: 19653732
[TBL] [Abstract][Full Text] [Related]
4. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
5. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
6. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
7. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
8. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
10. Malignant Mesothelioma Diagnosis.
Arif Q; Husain AN
Arch Pathol Lab Med; 2015 Aug; 139(8):978-80. PubMed ID: 26230591
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.
Hjerpe A; Ascoli V; Bedrossian CWM; Boon ME; Creaney J; Davidson B; Dejmek A; Dobra K; Fassina A; Field A; Firat P; Kamei T; Kobayashi T; Michael CW; Önder S; Segal A; Vielh P
Acta Cytol; 2015; 59(1):2-16. PubMed ID: 25824655
[TBL] [Abstract][Full Text] [Related]
12. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.
Hjerpe A; Ascoli V; Bedrossian CW; Boon ME; Creaney J; Davidson B; Dejmek A; Dobra K; Fassina A; Field A; Firat P; Kamei T; Kobayashi T; Michael CW; Önder S; Segal A; Vielh P; ;
Diagn Cytopathol; 2015 Jul; 43(7):563-76. PubMed ID: 26100969
[TBL] [Abstract][Full Text] [Related]
14. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Takeshima Y; Kohno H; Kushitani K; Yamada T; Morimoto C; Inai K
Histopathology; 2009 Jul; 55(1):10-9. PubMed ID: 19614762
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.
Chapel DB; Husain AN; Krausz T
Mod Pathol; 2019 Mar; 32(3):376-386. PubMed ID: 30315275
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
